| scholarly article | Q13442814 |
| P2093 | author name string | Y Li | |
| A D Michelson | |||
| A L Frelinger | |||
| M D Linden | |||
| M I Furman | |||
| M L Fox | |||
| M R Barnard | |||
| T J McLaughlin | |||
| W C Lau | |||
| P2860 | cites work | Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance | Q28166663 |
| Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction | Q28168881 | ||
| Platelet function testing in cardiovascular diseases | Q28171455 | ||
| Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial | Q28181168 | ||
| High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome | Q28194081 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| The difference between clopidogrel responsiveness and posttreatment platelet reactivity | Q28210845 | ||
| Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213372 | ||
| Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance | Q28213734 | ||
| Estimating the Dimension of a Model | Q29542197 | ||
| Lineage-specific overexpression of the P2Y1 receptor induces platelet hyper-reactivity in transgenic mice. | Q44518948 | ||
| Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. | Q44545487 | ||
| Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization | Q44768151 | ||
| High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. | Q45136309 | ||
| Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. | Q45165021 | ||
| Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases | Q45213002 | ||
| Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study | Q45287859 | ||
| Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop | Q45305235 | ||
| Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention | Q46421411 | ||
| The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting | Q46464355 | ||
| Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study | Q46802481 | ||
| Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction | Q49031698 | ||
| Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction | Q56945105 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clopidogrel | Q410237 |
| P304 | page(s) | 75-81 | |
| P577 | publication date | 2007-01-01 | |
| P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
| P1476 | title | Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance' | |
| P478 | volume | 5 |
| Q46799089 | A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: a practical guide. |
| Q38037121 | Advances in the monitoring of anti-P2Y12 therapy. |
| Q37443855 | Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? |
| Q37738868 | Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors |
| Q37684794 | Antiplatelet therapies for the treatment of cardiovascular disease |
| Q37313410 | Antithrombotic therapies in primary angioplasty: rationale, results and future directions |
| Q45180360 | Aspirin Half Maximal Inhibitory Concentration Value on Platelet Cyclooxygenase1 in Severe Type-2 Diabetes Mellitus is not Significantly Different from that of Healthy Individuals |
| Q37164379 | Assessing the current role of platelet function testing. |
| Q37067222 | Associations of CYP3A4, NR1I2, CYP2C19 and P2RY12 polymorphisms with clopidogrel resistance in Chinese patients with ischemic stroke |
| Q43255959 | Clinical management of clopidogrel inefficiency by point of care platelet function testing and individual adjustment of anti-platelet therapy--initial experiences |
| Q50275956 | Does Preoperative Platelet Function Predict Bleeding in Patients Undergoing Off Pump Coronary Artery Bypass Surgery? |
| Q58565792 | Early prediction of severity in acute ischemic stroke and transient ischemic attack using platelet parameters and neutrophil-to-lymphocyte ratio |
| Q37942701 | Glycoprotein IIb-IIIa inhibitors |
| Q30450312 | High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study |
| Q34768373 | Infection-associated platelet dysfunction of canine platelets detected in a flow chamber model |
| Q37175783 | Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study |
| Q41480353 | Multiple recurrent stent thrombosis in a patient with coexisting clopidogrel resistance and increased anticardiolipin antibodies: a case report. |
| Q46077297 | Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response |
| Q28221566 | Platelet function testing: state of the art |
| Q33420627 | RASA3 is a critical inhibitor of RAP1-dependent platelet activation |
| Q33775718 | Remote Assessment of Platelet Function in Patients with Acute Stroke or Transient Ischaemic Attack |
| Q43246022 | The risk of stent thrombosis in the perioperative setting |
| Q37576116 | Thienopyridine therapy and risk for cardiovascular events in secondary prevention |
| Q43205521 | Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel |
Search more.